Current Research Trials
Sydney Retina Clinic and Day Surgery is proud to be associated with a research department named the Sydney Institute of Vision Science. All members of the research team have a strong background in both clinical and laboratory research and are dedicated to the development of new treatment for retinal disease.
A Clinical effectiveness, multicentre, randomized, double masked, active controlled study of the efficacy and safety of ONS-5010 in subjects with subfoveal Choroidal Neovascularization (CNV) secondary to age-related macular degeneration (AMD).
OPT-302 in combination with aflibercept for persistent central-involved Diabetic Macular Edema (DME).
The Rhine study is a phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of RO6867461 in patients with Diabetic Macular Edema (DME).
The OTX-TKI study is a phase 1 open-label, dose escalation study of OTX-TKI (axitinib implant) for intravitreal use in subjects with neovascular Age-related macular degeneration (AMD).
SEQUOIA is a global, randomised, active controlled study which evaluates the safety and efficacy of Abicipar as a treatment for Neovascular Age-Related Macular Degeneration (AMD).
A two-year, three arm, randomized, Double-Masked, Multicenter, Phase 3 study assessing the efficacy and safety of Brolucizumab versus Aflibercept in adult patients with visual impairment due to Diabetic Macular Edema (DME).
Study of safety and tolerability of intravitreal Fludrocortisone Acetate (FCA) in patients with Geographic Atrophy (GA).
A multicentre, double-masked, randomized, dose-ranging trial to evaluate the efficacy and safety of Conbercept intravitreal injection in subjects with Neovascular Aged-related Macular Degeneration (AMD).
Investigator Initiated Studies
Clinicopathological Correlation in Macular Degeneration.
Intravitreal Aflibercept for the treatment of treatment resistant retinal vein occlusions.